Hemogenyx Pharmaceuticals Plc (HOPHF)
USD 1.24
(0.0%)
USD 1.24
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -5.33 Million GBP | -55.81% |
| 2022 | -5.44 Million GBP | -33.79% |
| 2021 | -2.55 Million GBP | -30.87% |
| 2020 | -2.08 Million GBP | -43.53% |
| 2019 | -1.62 Million GBP | 7.2% |
| 2018 | -1.63 Million GBP | -113.88% |
| 2017 | -837.06 Thousand GBP | -125.67% |
| 2016 | -447.15 Thousand GBP | -2659.6% |
| 2015 | -0.59 GBP | -75.74% |
| 2014 | -6270.00 GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1287.17 GBP | 99.9% |
| 2024 Q1 | -1287.17 GBP | -109.86% |
| 2023 Q3 | -613.35 GBP | 99.98% |
| 2023 FY | - GBP | -43.53% |
| 2023 Q4 | -613.35 GBP | 0.0% |
| 2023 Q2 | -3.89 Million GBP | -189665.46% |
| 2023 Q1 | -2053.22 GBP | 99.91% |
| 2022 Q1 | -555.51 GBP | 99.96% |
| 2022 FY | - GBP | -33.79% |
| 2022 Q3 | -2177.51 GBP | 99.8% |
| 2022 Q4 | -2.32 Million GBP | -106556.88% |
| 2022 Q2 | -1.11 Million GBP | -199900.0% |
| 2021 Q1 | -549.66 GBP | 99.95% |
| 2021 FY | - GBP | -30.87% |
| 2021 Q4 | -1.47 Million GBP | -195094.34% |
| 2021 Q3 | -756.73 GBP | 99.93% |
| 2021 Q2 | -1.09 Million GBP | -199900.0% |
| 2020 Q3 | -609.75 GBP | 99.93% |
| 2020 Q2 | -861.03 Thousand GBP | -199899.54% |
| 2020 Q4 | -1.18 Million GBP | -193849.29% |
| 2020 Q1 | -430.52 GBP | 99.95% |
| 2020 FY | - GBP | -43.53% |
| 2019 FY | - GBP | 7.2% |
| 2019 Q4 | -829.81 Thousand GBP | -191147.17% |
| 2019 Q3 | -433.89 GBP | 99.94% |
| 2019 Q2 | -759.6 Thousand GBP | -199900.53% |
| 2019 Q1 | -379.80 GBP | 16.96% |
| 2018 Q3 | -457.37 GBP | -27.85% |
| 2018 Q2 | -357.74 GBP | 0.0% |
| 2018 Q4 | -457.37 GBP | 0.0% |
| 2018 Q1 | -357.74 GBP | -16.11% |
| 2018 FY | - GBP | -113.88% |
| 2017 Q4 | -308.10 GBP | 0.0% |
| 2017 FY | - GBP | -125.67% |
| 2017 Q1 | -110.43 GBP | 0.0% |
| 2017 Q3 | -308.10 GBP | -179.01% |
| 2017 Q2 | -110.43 GBP | -0.0% |
| 2016 FY | - GBP | -2659.6% |
| 2015 FY | - GBP | -75.74% |
| 2014 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 92.492% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 10.048% |
| SQZ Biotechnologies Company | -64.14 Million USD | 91.685% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 69.297% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 105.671% |
| Mesoblast Limited | -62.38 Million USD | 91.452% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -247.199% |
| Genus plc | 73.7 Million USD | 107.236% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 19.336% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -50.357% |
| Marizyme, Inc. | -34.28 Million USD | 84.443% |
| ContraFect Corporation | -64.99 Million USD | 91.795% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 39.203% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -17.828% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -280.448% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -101.673% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -129.499% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -929.474% |
| Accustem Sciences Inc. | -3.74 Million USD | -42.353% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 88.942% |
| EV Biologics, Inc. | -1.26 Million USD | -320.883% |
| Q BioMed Inc. | -617.62 Thousand USD | -763.489% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 249.304% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -743.311% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -133.45% |
| Biomind Labs Inc. | -1.03 Million USD | -415.505% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 153.996% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 25.528% |
| Skye Bioscience, Inc. | -13.54 Million USD | 60.634% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -258.552% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -21232.588% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -37.299% |
| IMV Inc. | -35.52 Million USD | 84.987% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 66.394% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -113.159% |
| GB Sciences, Inc. | -1.41 Million USD | -275.604% |
| Alpha Cognition Inc. | -9.7 Million USD | 45.051% |
| HST Global, Inc. | -5303.00 USD | -100468.49% |
| CSL Limited | 4.78 Billion USD | 100.111% |
| Halberd Corporation | -74.27 Thousand USD | -7079.885% |
| Enzolytics Inc. | -2.12 Million USD | -151.323% |
| Resverlogix Corp. | -11.74 Million USD | 54.581% |
| Affymax, Inc. | -14.29 Million USD | 62.692% |
| SYBLEU INC | -141.57 Thousand USD | -3667.118% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -74.114% |
| argenx SE | -216.02 Million USD | 97.531% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 90.363% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 538.221% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -255.803% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1507.742% |
| AVAX Technologies, Inc. | -6.11 Million USD | 12.752% |
| Zenith Capital Corp. | -8.6 Million USD | 38.03% |
| Genscript Biotech Corporation | -248.71 Million USD | 97.856% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -30513.323% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -117.994% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2929.778% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 86.545% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -84.39% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -409.709% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 79415.095% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -204.751% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -177.636% |
| BioStem Technologies, Inc. | -7.55 Million USD | 29.396% |
| ONE Bio Corp. | 13.61 Million USD | 139.177% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -2845.058% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -159.268% |
| Agentix Corp. | -1.37 Million USD | -288.782% |
| LadRx Corporation | 412.28 Thousand USD | 1393.565% |
| Cell Source, Inc. | -4.27 Million USD | -24.824% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1352.299% |
| Regen BioPharma, Inc. | 1.46 Million USD | 463.8% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -469.204% |
| NovAccess Global Inc. | -1.03 Million USD | -415.381% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 160.236% |
| Itoco Inc. | -1.86 Million USD | -185.348% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1304.865% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -377.881% |
| Kadimastem Ltd | -2.62 Million USD | -103.215% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -2130.043% |
| CytoDyn Inc. | -18.02 Million USD | 70.419% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -6648.342% |
| Mobile Lads Corp. | -2.24 Million USD | -137.964% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -43510.655% |
| Qrons Inc. | -40.08 Thousand USD | -13205.923% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -998.083% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1111.152% |
| Rebus Holdings, Inc. | -951 Thousand USD | -460.794% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -402.175% |
| International Stem Cell Corporation | 202 Thousand USD | 2740.172% |
| Bioxytran, Inc. | -3.82 Million USD | -39.606% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -10031.358% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -116.624% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 85.132% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -11751.438% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -94.783% |
| Neutra Corp. | -181.24 Thousand USD | -2842.475% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 73.545% |
| PureTech Health plc | -11.62 Million USD | 54.131% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 73.543% |
| IXICO plc | -707 Thousand USD | -654.335% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 30.603% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 88.969% |
| CSL Limited | 4.73 Billion USD | 100.113% |
| Cellectis S.A. | -92.63 Million USD | 94.243% |